| Literature DB >> 28413700 |
Gry N Behzadi1, Lars Fjetland1, Rajiv Advani2, Martin W Kurz2, Kathinka D Kurz1,3.
Abstract
INTRODUCTION: Our purpose was to evaluate the safety and efficacy of endovascular treatment (EVT) of stroke caused by large vessel occlusions (LVO) performed by general interventional radiologists in cooperation with stroke neurologists and neuroradiologists at a center with a limited annual number of procedures. We aimed to compare our results with those previously reported from larger stroke centers. PATIENTS AND METHODS: A total of 108 patients with acute stroke due to LVO treated with EVT were included. Outcome was measured using the modified Rankin scale (mRS) at 90 days. Efficacy was classified according to the modified thrombolysis in cerebral infarction (mTICI) scoring system. Safety was evaluated according to the incidence of procedural complications and symptomatic intracranial hemorrhage (sICH).Entities:
Keywords: endovascular treatment; general interventional radiologists; ischemic stroke; large vessel occlusions; stroke centers
Mesh:
Year: 2017 PMID: 28413700 PMCID: PMC5390832 DOI: 10.1002/brb3.642
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Equipment used by the reperfusion procedure
| Anterior circulation | Posterior circulation | |
|---|---|---|
| Mechanical thrombectomy with aspiration | ||
| Microcatheter | Prowler Select + | Prowler Select + |
| Guidewire 0,035 | Glidewire | Glidewire |
| Advantage | Advantage | |
| Microguidewire | Fathom‐016 | Fathom‐016 |
| Journey | Journey | |
| Guiding catheter | Neuron 6F | Neuron 6F |
| Destination 6F | Destination 6F | |
| ENVOY | ||
| Strada Carotid Guiding Sheath | ||
| Aspiration catheter | Penumbra Reperfusion Catheter 041 | Penumbra Reperfusion Catheter 041 |
| Penumbra Reperfusion Catheter 032 | Penumbra Reperfusion Catheter 032 | |
| Penumbra Reperfusion Catheter 026 | Penumbra Reperfusion Catheter 026 | |
| Mechanical thrombectomy with stent retriever | ||
| Microcatheter | Rebar | Rebar |
| Microguidewire | Fathom‐016 | Fathom‐016 |
| Journey | Journey | |
| Guiding catheter | Destination 6F | Destination 6F |
| Neuron 6F | Neuron 6F | |
| Strada Carotid Guiding Sheath | ||
| Aspiration catheter | Penumbra ACE 64 | Penumbra ACE 64 |
| Penumbra 5 MAX | Penumbra 5 MAX | |
| Stent retriever | Solitaire AB/FR | Solitaire AB/FR |
| Stents and balloons | ||
| Carotic stent | Adapt carotid stent 4‐9mm | |
| Intracranial stent | Wingspan 2.5‐4.5mm | Wingspan 2.5‐4.5mm |
| Balloon | Gateway | Gateway |
Codman & Shurtleff, Inc. Raynham, MA, USA.
Terumo Medical Corporation, Somerset, NJ USA.
Boston Scientific Corporation, Natick, MA, USA.
Penumbra Inc. Alameda, CA, USA.
St. Jude Medical Inc. St. Paul, MN, USA.
Microtherapeutics, ev3, Irvine, CA, USA.
Patient baseline characteristics and cardiovascular risk factors
| Mean years of age (range) | 67.5 (31–92) |
| Female gender (%) | 42 (38.9) |
| Cardiovascular burden (%) | |
| Hypertension | 61 (56.5) |
| Diabetes mellitus | 12 (11.1) |
| Previous cardiovascular events | 14 (13.0) |
| Previous cerebral vascular events | 14 (13. 0) |
Site of occlusion and clinical outcome at 90 days
|
| mRS 0–2 (%) | |
|---|---|---|
| ICA | 4 (3.7) | 0 |
| Carotid T | 10 (9.3) | 4 (40) |
| Tandem lesions | 23 (21.3) | 9 (39.1) |
| MCA | 55 (50.9) | 23 (41.8) |
| Basilar artery | 16 (14.8) | 7 (43.8) |
Internal carotid artery.
Tandem lesions: ICA and MCA.
MCA: middle cerebral artery.
Angiographic result by mTICI score
| Angiographic result | Total ( | Anterior circulation ( | Posterior circulation ( |
|---|---|---|---|
| mTICI 0 | 8 (7.4) | 4 (4.4) | 4 (25) |
| mTICI 1 | 8 (7.4) | 7 (7.6) | 1 (6.3) |
| mTICI 2a | 10 (9.3) | 9 (9.8) | 1 (6.3) |
| mTICI 2b | 39 (36.1) | 37 (40.2) | 2 (12.5) |
| mTICI 3 | 43 (39.8) | 35 (38.0) | 8 (50) |
Patient outcomes and complications
| NIHSS before treatment | NIHSS after treatment | NIHSS on discharge | mRS | Mortality | sICH | Intraprocedural complications | |
|---|---|---|---|---|---|---|---|
| All patients | 17 (105) | 13 (100) | 6 (84) | 3.5 (108) | 23 (108) 21.3% |
8 (108) |
8 (108) |
| mTICI 2b‐3 | 17.5 (82) | 9.5 (82) | 5 (77) | 2 (75) |
8 (82) |
3 (82) |
4 (82) |
| mTICI 0‐2a | 17 (23) | 20 (19) | 15.5 (10) | 6 (23) |
15 (23) |
5 (23) |
4 (23) |
|
| .97 | <.001 | <.001 | <.001 | <.001 | .04 | .33 |
Median.
3 months.
() number of patients.